Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review(S)-WAY 100135 dihydrochloride
说明： Potent and selective 5-HT1A antagonist
化学名： (S)-N-tert-Butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide dihydrochloride
纯度： ≥99% (HPLC)
生物活性 for (S)-WAY 100135 dihydrochloride
(S)-WAY 100135 dihydrochloride is a potent, selective 5-HT1A receptor antagonist (IC50 = 15 nM). Selective over 5-HT1B, 1C, 2,α1, α2 and D2 receptors (IC50 > 1000 nM). Centrally active on systemic administration.
许可信息
Sold with the permission of Wyeth-Ayerst Research, US Patent 4,988,814
化合物库 for (S)-WAY 100135 dihydrochloride
(S)-WAY 100135 dihydrochloride is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。
技术数据 for (S)-WAY 100135 dihydrochloride
| 分子量 | 468.47 |
| 公式 | C24H33N3O2.2HCl |
| 储存 | Desiccate at +4°C |
| 纯度 | ≥99% (HPLC) |
| CAS Number | 149007-54-5 |
| PubChem ID | 6604839 |
| InChI Key | NYZFUZCCDOSQBG-AWEZNQCLSA-N |
| Smiles | O=C(NC(C)(C)C)[C@@]([C@]3=CC=CC=C3)([H])CN(CC2)CCN2C1=C(OC)C=CC=C1.Cl.Cl |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for (S)-WAY 100135 dihydrochloride
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| DMSO | 46.85 | 100 | |
| water | 2.34 | 5 温和加热 | |
| water | 4.68 | 10 超声处理 |
制备储备液 for (S)-WAY 100135 dihydrochloride
以下数据基于产品分子量 468.47。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.13 mL | 10.67 mL | 21.35 mL |
| 5 mM | 0.43 mL | 2.13 mL | 4.27 mL |
| 10 mM | 0.21 mL | 1.07 mL | 2.13 mL |
| 50 mM | 0.04 mL | 0.21 mL | 0.43 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for (S)-WAY 100135 dihydrochloride
参考文献 for (S)-WAY 100135 dihydrochloride
参考文献是支持产品生物活性的出版物。
Cliffe et al (1993) (S)-N-tert-Butyl-3(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: a selective antagonist at presynaptic and postsynaptic 5-HT1A receptors. J.Med.Chem. 36 1509 PMID: 8496920
Fletcher et al (1993) WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors. Eur.J.Pharmacol. 237 283 PMID: 8365456
Fletcher et al (1993) Silent 5-HT1A receptor antagonists: utility as research tools and therapeutic agents. Trends Pharmacol.Sci. 14 41 PMID: 8122313
Rodgers and Cole (1994) Anxiolytic-like effect of (S)-WAY 100135, a 5-HT1A receptor antagonist, in the murine elevated plus-maze test. Eur.J.Pharmacol. 261 321 PMID: 7813555
If you know of a relevant reference for (S)-WAY 100135 dihydrochloride, please let us know.
按标靶查看相关产品
按产品操作查看相关产品
关键词: (S)-WAY 100135 dihydrochloride, (S)-WAY 100135 dihydrochloride supplier, Potent, selective, 5-HT1A, antagonist, Serotonin, Receptors, (S)-WAY100135, dihydrochloride, 1253, Tocris Bioscience
7 篇 (S)-WAY 100135 dihydrochloride 的引用文献
引用文献是使用了 Tocris 产品的出版物。 (S)-WAY 100135 dihydrochloride 的部分引用包括：
Chambers et al (2011) Multiple neural oscillators and muscle feedback are required for the intestinal fed state motor program. PLoS One 6 e19597 PMID: 21573176
Pandya and Yakel (2013) Activation of the α7 nicotinic ACh receptor induces anxiogenic effects in rats which is blocked by a 5-HT?a receptor antagonist. Neuropharmacology 70 35 PMID: 23321689
Saxena et al (2013) Neuroprotection through excitability and mTOR required in ALS motoneurons to delay disease and extend survival. Neuron 80 80 PMID: 24094105
Borroto-Escuela et al (2012) The existence of FGFR1-5-HT1A receptor heterocomplexes in midbrain 5-HT neurons of the rat: relevance for neuroplasticity. J Neurosci 32 6295 PMID: 22553035
Grace et al (2012) 5-HT1A receptor-responsive pedunculopontine tegmental neurons suppress REM sleep and respiratory motor activity. J Neurosci 32 1622 PMID: 22302804
Foong et al (2010) 5-HT(1A), SST(1), and SST(2) receptors mediate inhibitory postsynaptic potentials in the submucous plexus of the guinea pig ileum. J Neurosci 298 G384 PMID: 20007849
Hampson et al (2007) Stimulation of glycogen synthesis and inactivation of phosphorylase in hepatocytes by serotonergic mechanisms, and counter-regulation by atypical antipsychotic drugs. Diabetologia 50 1743 PMID: 17579833
您是否知道使用了 Tocris (S)-WAY 100135 dihydrochloride 的优秀论文？ 请告知我们.
(S)-WAY 100135 dihydrochloride 的评论
目前没有该产品的评论。 Be the first to review (S)-WAY 100135 dihydrochloride and earn rewards!
Have you used (S)-WAY 100135 dihydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.